Randomized phase 2 study of gemcitabine with or without ATR inhibitor berzosertib in platinum-resistant ovarian cancer: Final overall survival (OS) and biomarker analyses.

Authors :: Konstantinopoulos, Panagiotis A.
Lee, Elizabeth Katherine
Cheng, SuChun
Da Costa, Alexandre Andre B. A.
Wahner Hendrickson, Andrea Elisabeth
Gulhan, Doga
Kochupurakkal, Bose
Kolin, David
Kohn, Elise C.
Liu, Joyce F.
Stover, Elizabeth
Curtis, Jennifer
Sawyer, Hannah
Polak, Madeline
Chowdhury, Dipanjan
Färkkilä, Anniina
D'Andrea, Alan D.
Shapiro, Geoffrey
Matulonis, Ursula A.
Source :: Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p5512-5512, 1p
Publication Year :: 2023

Full Text Access

Tools